Komatsu M, Ishii T, Ono T, Hoshino T, Kuramitsu T, Goto T, Fujii T, Toyoshima I, Chiba M, Masamune O
Department of Internal Medicine, Akita University School of Medicine, Japan.
Can J Gastroenterol. 1997 Sep;11(6):507-11. doi: 10.1155/1997/627297.
A controlled trial comparing combination therapy with ofloxacin (OFLX) and interferon (IFN) versus IFN monotherapy was conducted in patients with chronic hepatitis C who failed IFN therapy. Twenty patients were assigned randomly to two groups. Equal doses of recombinant IFN alpha-2b were administered to each group for 24 weeks. For the IFN plus OFLX group, OFLX was administered for 12 weeks at a daily dose of 600 mg. Levels of hepatitis C virus RNA declined significantly from the first month after the start of IFN treatment compared with those before administration in both groups. Serum alanine aminotransferase levels were significantly lower in the IFN plus OFLX group at two and six months after the start of treatment than levels in the IFN group. The fraction of subjects whose levels of serum ALT normalized was also higher in the IFN plus OFLX group. Larger clinical trials should be undertaken.
对干扰素（IFN）治疗失败的慢性丙型肝炎患者进行了一项对照试验，比较氧氟沙星（OFLX）与干扰素联合治疗和干扰素单一疗法。20名患者被随机分为两组。每组给予等量的重组干扰素α-2b，持续24周。对于干扰素加OFLX组，OFLX以每日600毫克的剂量给药12周。与给药前相比，两组在开始干扰素治疗后的第一个月，丙型肝炎病毒RNA水平均显著下降。治疗开始后两个月和六个月时，干扰素加OFLX组的血清丙氨酸氨基转移酶水平显著低于干扰素组。干扰素加OFLX组中血清ALT水平恢复正常的受试者比例也更高。应开展更大规模的临床试验。
